PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
1-Hydroxy-Vitamin-D Treatment May Improve Outcomes in HOSPITALIZED PATIENTS WITH COVID-19, Reducing Composite Outcomes Including The Need For Additional Respiratory Support And In-Hospital Mortality . ...